Skip to main content

Cell, Tissue and Gene Therapy

Section edited by David Stroncek

This section aims to improve communication between basic and clinical research related to cell, tissue and gene therapies. Effective clinical therapies require efficient translation of research between the bench and bedside to allow the discovery, development, scale up, and production of cells, tissues and vectors. These therapies are being used to treat patients with a range of diseases including cancer, cardiovascular diseases, autoimmune disorders.

Studies considered for publication include those regarding the nature of cells, tissues and vectors used in clinical therapies; methods to collect, isolate and modify cells; and novel reagents, equipment, and instruments used in production. The section also welcomes research into the application of clinical therapies; factors that effect the safety and efficacy; in particular the potency, stability and purity of cells or tissue; and issues related to the safety of cell and tissue donors.

Featured articles

Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction

Research | Mark Bieri et al


Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients​​​​​​​

Review | Christopher J. Rogers et al


Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak

Review |  Michael Har-Noy & Reuven Or 

Page 2 of 10

  1. Although mRNA vaccines have overall efficacy preventing morbidity/mortality from SARS-CoV-2 infection, immunocompromised persons remain at risk. Antibodies mostly prevent early symptomatic infection, but cellu...

    Authors: Ellie Taus, Michael Y. Shino, F. Javier Ibarrondo, Mary Ann Hausner, Christian Hofmann and Otto O. Yang
    Citation: Journal of Translational Medicine 2023 21:374
  2. Glioblastoma multiforme (GBM) is associated with remarkably poor prognosis, and its treatment is challenging. This investigation aimed to evaluate the safety of suicide gene therapy using allogeneic adipose ti...

    Authors: Saeed Oraee-Yazdani, Roozbeh Tavanaei, Fatemeh Rostami, Atieh Hajarizadeh, Marzieh Mehrabadi, Mohammadhosein Akhlaghpasand, Mona Tamaddon, Samin Khannejad, Kaveh Oraii Yazdani and Alireza Zali
    Citation: Journal of Translational Medicine 2023 21:350
  3. The success of allogeneic hematopoietic stem cell transplant for hematological malignancies is heavily dependent on the availability of suitable donors. Haploidentical donor (HID) and matched sibling donor (MS...

    Authors: Hengwei Wu, Yeqian Zhao, Fei Gao, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Pengxu Qian, He Huang and Yanmin Zhao
    Citation: Journal of Translational Medicine 2023 21:329
  4. Multiple preclinical studies have reported a beneficial effect of extracellular vesicles (EVs), especially mesenchymal stem cells derived EVs (MSC-EVs), in the treatment of sepsis. However, the therapeutic eff...

    Authors: Shujun Yang, Kanglong Zhang, Jingyu Hou, Xin Liu, Daishi Xu, Xuxiang Chen, Shuangmei Li, Yinghui Hong, Changqing Zhou, Hao Wu, Guanghui Zheng, Chaotao Zeng, Haidong Wu, Jiaying Fu and Tong Wang
    Citation: Journal of Translational Medicine 2023 21:262
  5. The claudin 18.2 (CLDN18.2) antigen is frequently expressed in malignant tumors, including pancreatic ductal adenocarcinoma (PDAC). Although CLDN18.2-targeted CAR-T cells demonstrated some therapeutic efficacy...

    Authors: Yifan Liu, Yansha Sun, Peng Wang, Songling Li, Yiwei Dong, Min Zhou, Bizhi Shi, Hua Jiang, Ruixin Sun and Zonghai Li
    Citation: Journal of Translational Medicine 2023 21:255
  6. Bloodstream infection (BSI) is a serious hematopoietic stem cell transplantation (HSCT) complication. The intestinal microbiome regulates host metabolism and maintains intestinal homeostasis. Thus, the impact ...

    Authors: Guankun Yin, Yifan Guo, Qi Ding, Shuai Ma, Fengning Chen, Qi Wang, Hongbin Chen and Hui Wang
    Citation: Journal of Translational Medicine 2023 21:230
  7. Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potentia...

    Authors: Weiqian Hu, Weijun Wang, Xin Jiang, Zeyu Wang and Rong Lin
    Citation: Journal of Translational Medicine 2023 21:227
  8. CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in treating relapsed or refractory pediatric B-lineage acute lymphoblastic leukemia (B-ALL). However, poor results a...

    Authors: Wenjie Li, Lixia Ding, Wenhua Shi, Xinyu Wan, Xiaomin Yang, Jing Yang, Tianyi Wang, Lili Song, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang…
    Citation: Journal of Translational Medicine 2023 21:213
  9. Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological maligna...

    Authors: Piotr Celichowski, Marcello Turi, Sandra Charvátová, Dhwani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Šimíček, Tomáš Jelínek, Juli Rodriguez Bago, Roman Hájek and Matouš Hrdinka
    Citation: Journal of Translational Medicine 2023 21:197
  10. Inherited retinal degeneration is a leading cause of incurable vision loss in the developed world. While autologous iPSC mediated photoreceptor cell replacement is theoretically possible, the lack of commercia...

    Authors: Laura R. Bohrer, Nicholas E. Stone, Nathaniel K. Mullin, Andrew P. Voigt, Kristin R. Anfinson, Jessica L. Fick, Viviane Luangphakdy, Bradley Hittle, Kimerly Powell, George F. Muschler, Robert F. Mullins, Edwin M. Stone and Budd A. Tucker
    Citation: Journal of Translational Medicine 2023 21:161
  11. Chimeric antigen receptor (CAR)-T cell therapies for the treatment of hematological malignancies experienced tremendous progress in the last decade. However, essential limitations need to be addressed to furt...

    Authors: Zhifen Yang, Violena Pietrobon, Maggie Bobbin, Ofir Stefanson, Jin Yang, Angshumala Goswami, Bennett Alphson, Hana Choi, Khristina Magallanes, Qi Cai, David Barrett, Bing Wang, Lei S. Qi and Francesco M. Marincola
    Citation: Journal of Translational Medicine 2023 21:158
  12. Malfunction of astrocytes is implicated as one of the pathological factors of ALS. Thus, intrathecal injection of healthy astrocytes in ALS can potentially compensate for the diseased astrocytes. AstroRx® is a...

    Authors: Marc Gotkine, Yoseph Caraco, Yossef Lerner, Simcha Blotnick, Maor Wanounou, Shalom Guy Slutsky, Judith Chebath, Graciela Kuperstein, Elena Estrin, Tamir Ben-Hur, Arik Hasson, Kfir Molakandov, Tehila Sonnenfeld, Yafit Stark, Ariel Revel, Michel Revel…
    Citation: Journal of Translational Medicine 2023 21:122
  13. Large extracellular vesicles (L-EV) with a diameter between 1 and 10 µm are released by various cell types. L-EV contain and transport active molecules which are crucially involved in cell to cell communicatio...

    Authors: Martin Albrecht, Lars Hummitzsch, Rene Rusch, Katharina Heß, Markus Steinfath, Jochen Cremer, Frank Lichte, Fred Fändrich, Rouven Berndt and Karina Zitta
    Citation: Journal of Translational Medicine 2023 21:61
  14. Chimeric antigen receptor T (CAR-T) cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells. Despite several CAR-T products being appro...

    Authors: Haiying Wang, Shih-Ting Tsao, Mingyuan Gu, Chengbing Fu, Feng He, Xiu Li, Mian Zhang, Na Li and Hong-Ming Hu
    Citation: Journal of Translational Medicine 2022 20:608
  15. The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used f...

    Authors: Yu Lu, Ying Liu, Shupeng Wen, Na Kuang, Xuejun Zhang, Jianqiang Li and Fuxu Wang
    Citation: Journal of Translational Medicine 2022 20:600
  16. It has been well-documented that haplo-identical hematopoietic stem cell transplantation (HID-HSCT) can provide outcomes comparable to conventional matched sibling donor (MSD) HSCT, however, little is known ab...

    Authors: Xiaoyu Zhang, Jiao Wang, Yuqiu Liu, Jie Liu, Bei Wang, Qiuhui Zhang, Wei Guan, Huijuan Zhang, Li Xu, Guiying Liu, Ping Zhang, Yi He, Sizhou Feng, Mingzhe Han, Changping Li, Erlie Jiang…
    Citation: Journal of Translational Medicine 2022 20:596
  17. SARS-CoV2 can induce a strong host immune response. Many studies have evaluated antibody response following SARS-CoV2 infections. This study investigated the immune response and T cell receptor diversity in pe...

    Authors: Mallikarjuna R. Gedda, Patrick Danaher, Lipei Shao, Martin Ongkeko, Leonard Chen, Anh Dinh, Mame Thioye Sall, Opal L. Reddy, Christina Bailey, Amy Wahba, Inna Dzekunova, Robert Somerville, Valeria De Giorgi, Ping Jin, Kamille West, Sandhya R. Panch…
    Citation: Journal of Translational Medicine 2022 20:587
  18. In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated...

    Authors: Mengmeng Liu, Lina Liu, Yongping Song, Wei Li and Linping Xu
    Citation: Journal of Translational Medicine 2022 20:586
  19. Abnormal gene expression level or expression of genes containing deleterious mutations are two of the main determinants which lead to genetic disease. To obtain a therapeutic effect and thus to cure genetic di...

    Authors: Hsing-Chuan Tsai, Violena Pietrobon, Maoyu Peng, Suning Wang, Lihong Zhao, Francesco M. Marincola and Qi Cai
    Citation: Journal of Translational Medicine 2022 20:535
  20. Circular ribonucleic acids (circRNAs) are a class of long non-coding RNA that were once regarded as non-functional transcription byproducts. However, recent studies suggested that circRNAs may exhibit importan...

    Authors: Ryan Wong, Yiwen Zhang, Hailin Zhao and Daqing Ma
    Citation: Journal of Translational Medicine 2022 20:533
  21. Chronic graft-versus-host disease (GVHD) is a major cause of late morbidity and non-relapse mortality in recipients of allogeneic hematopoietic cell transplantation (HCT). Its biology, however, remains poorly ...

    Authors: Alain Mina, Lauren Curtis, Kamille West, Yu Ying Yau, Edward W. Cowen, Frances Hakim and Steven Z. Pavletic
    Citation: Journal of Translational Medicine 2022 20:519
  22. Osteoarthritis (OA) is a chronic degenerative joint disease characterized by the destruction of the articular cartilage, sclerosis of the subchondral bone, and joint dysfunction. Its pathogenesis is attributed...

    Authors: Jianghong Huang, Qisong Liu, Jiang Xia, Xi Chen, Jianyi Xiong, Lei Yang and Yujie Liang
    Citation: Journal of Translational Medicine 2022 20:515
  23. Clinical CAR T-cell therapy using integrating vector systems represents a promising approach for the treatment of hematological malignancies. Lentiviral and γ-retroviral vectors are the most commonly used vect...

    Authors: Lipei Shao, Rongye Shi, Yingdong Zhao, Hui Liu, Alexander Lu, Jinxia Ma, Yihua Cai, Tatyana Fuksenko, Alejandra Pelayo, Nirali N. Shah, James N. Kochenderfer, Scott M. Norberg, Christian Hinrichs, Steven L. Highfill, Robert P Somerville, Sandhya R. Panch…
    Citation: Journal of Translational Medicine 2022 20:514
  24. Immune checkpoint inhibitors are promising tools in combating several cancers, including head and neck squamous cell carcinoma (HNSCC). However, a substantial portion of HNSCC patients do not respond to PD-L1 ...

    Authors: Shuang Li, Ding Wang, Jinzhang Cheng, Jicheng Sun, Dhan V. Kalvakolanu, Xue Zhao, Di Wang, Yunhan You, Ling Zhang and Dan Yu
    Citation: Journal of Translational Medicine 2022 20:505
  25. Autologous hematopoietic progenitor cell (HPC) transplantation is currently the standard of care for a fraction of patients with newly diagnosed myelomas and relapsed or refractory lymphomas. After high-dose c...

    Authors: Bechara Mfarrej, Olivier Vicari, Sarah Ouffai, Carine Malenfant, Angela Granata, Sophie Thevenet, Christian Chabannon, Claude Lemarié and Boris Calmels
    Citation: Journal of Translational Medicine 2022 20:503
  26. Chimeric antigen receptor (CAR)-T cell therapy is a powerful adoptive immunotherapy against both B-cell malignancies and some types of solid tumors. Interleukin (IL) -15 is an important immune stimulator that ...

    Authors: Ying Zhang, Qinghui Zhuang, Fang Wang, Can Zhang, Chang Xu, Aiqin Gu, William H. Zhong, Yi Hu and Xiaosong Zhong
    Citation: Journal of Translational Medicine 2022 20:432
  27. Currently, there is no regenerative therapy for patients with neurological and neurodegenerative disorders. Cell-therapies have emerged as a potential treatment for numerous brain diseases. Despite recent adva...

    Authors: Ruslan Rust, Rebecca Z. Weber, Melanie Generali, Debora Kehl, Chantal Bodenmann, Daniela Uhr, Debora Wanner, Kathrin J. Zürcher, Hirohide Saito, Simon P. Hoerstrup, Roger M. Nitsch and Christian Tackenberg
    Citation: Journal of Translational Medicine 2022 20:421
  28. Increasing evidence supports the concept of prenatal programming as an early factor in the aging process. DNA methylation age (DNAm age), global genome-wide DNA methylation (global methylation), telomere lengt...

    Authors: Brigitte Reimann, Dries S. Martens, Congrong Wang, Akram Ghantous, Zdenko Herceg, Michelle Plusquin and Tim S. Nawrot
    Citation: Journal of Translational Medicine 2022 20:353
  29. Cytokine release syndrome (CRS) is a strong immune system response that can occur as a result of the reaction of a cellular immunotherapy with malignant cells. While the frequency and management of CRS in CAR ...

    Authors: Lipei Shao, Alejandra Pelayo, Rongye Shi, Jinxia Ma, Hui Liu, Yihua Cai, Michaela Prochazkova, Robert P. Somerville, Sandhya R. Panch, Nirali N. Shah, David F. Stroncek and Ping Jin
    Citation: Journal of Translational Medicine 2022 20:338
  30. Despite promising results in clinical studies, the mechanism for the beneficial effects of allogenic cell-based therapies remains unclear. Macrophages are not only critical mediators of inflammation but also c...

    Authors: Rachana Mishra, Progyaparamita Saha, Srinivasa Raju Datla, Pranav Mellacheruvu, Muthukumar Gunasekaran, Sameer Ahmad Guru, Xuebin Fu, Ling Chen, Roberto Bolli, Sudhish Sharma and Sunjay Kaushal
    Citation: Journal of Translational Medicine 2022 20:323

    The Correction to this article has been published in Journal of Translational Medicine 2023 21:168

  31. Radiation-induced skin injury is a well-known risk factor for impaired wound healing. Over time, the deleterious effects of radiation on skin produce a fibrotic, hypovascular dermis poorly suited to wound heal...

    Authors: Hendrik Lintel, Darren B. Abbas, Christopher V. Lavin, Michelle Griffin, Jason L. Guo, Nicholas Guardino, Andrew Churukian, Geoffrey C. Gurtner, Arash Momeni, Michael T. Longaker and Derrick C. Wan
    Citation: Journal of Translational Medicine 2022 20:274
  32. Tumor-draining lymph nodes (TDLNs) are primary sites, where anti-tumor lymphocytes are primed to tumor-specific antigens and play pivotal roles in immune responses against tumors. Although adoptive cell therap...

    Authors: Kazumi Okamura, Satoshi Nagayama, Tomohiro Tate, Hiu Ting Chan, Kazuma Kiyotani and Yusuke Nakamura
    Citation: Journal of Translational Medicine 2022 20:241
  33. As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have recently gained attention as an important type of innate immune regulatory cell. NK cells can rapidly kill multipl...

    Authors: Junfeng Chu, Fengcai Gao, Meimei Yan, Shuang Zhao, Zheng Yan, Bian Shi and Yanyan Liu
    Citation: Journal of Translational Medicine 2022 20:240
  34. Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-u...

    Authors: Taku Kouro, Hidetomo Himuro and Tetsuro Sasada
    Citation: Journal of Translational Medicine 2022 20:239
  35. The two oncogenic human gammaherpesviruses, Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein–Barr virus (EBV), both downregulate immune surface molecules, such as MHC-I, ICAM-1, and B7-2, enabling them...

    Authors: Yiquan Wu, Prabha Shrestha, Natalie M. Heape and Robert Yarchoan
    Citation: Journal of Translational Medicine 2022 20:217
  36. Cellular therapies have become an important part of clinical care. The treatment of patients with cell therapies often involves the collection of autologous cells at the medical center treating the patient, th...

    Authors: David Stroncek, Anh Dinh, Herleen Rai, Nan Zhang, Rob Somerville and Sandhya Panch
    Citation: Journal of Translational Medicine 2022 20:184
  37. Diabetes mellitus (DM), currently affecting 463 million people worldwide is a chronic disease characterized by impaired glucose metabolism resulting from the loss or dysfunction of pancreatic β-cells with the ...

    Authors: Abdoulaye Diane, Noora Ali Al-Shukri, Razik Bin Abdul Mu-u-min and Heba H. Al-Siddiqi
    Citation: Journal of Translational Medicine 2022 20:163
  38. The NK cell line NK-92 and its genetically modified variants are receiving attention as immunotherapies to treat a range of malignancies. However, since NK-92 cells are themselves tumors, they require irradiat...

    Authors: Lydia Navarrete-Galvan, Michael Guglielmo, Judith Cruz Amaya, Julie Smith-Gagen, Vincent C. Lombardi, Rebecca Merica and Dorothy Hudig
    Citation: Journal of Translational Medicine 2022 20:151
  39. Nanocarriers as drug/biomolecule delivery systems have been significantly developed during recent decades. Given the stability, reasonable delivery efficiency, and safety of nanocarriers, there are several bar...

    Authors: Ala Amiri, Rafieh Bagherifar, Ehsan Ansari Dezfouli, Seyed Hossein Kiaie, Reza Jafari and Reihaneh Ramezani
    Citation: Journal of Translational Medicine 2022 20:125
  40. Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable new treatment option for patients with B-cell malignancies. However, by applying selective pressure, outgrowth of antigen-negative tum...

    Authors: Gils Roex, Diana Campillo-Davo, Donovan Flumens, Philip Anthony Gilbert Shaw, Laurens Krekelbergh, Hans De Reu, Zwi N. Berneman, Eva Lion and Sébastien Anguille
    Citation: Journal of Translational Medicine 2022 20:124
  41. The transformation of hepatic stellate cell (HSC) to myofibroblast is a key event during liver fibrogenesis. However, the differentiation trajectory of HSC-to-myofibroblast transition and the switching genes d...

    Authors: Hua Wang, Shaoping Zheng, Hongbo Jiang, Xuejia Wang, Fengqin Zhou and Zhihong Weng
    Citation: Journal of Translational Medicine 2022 20:53
  42. The use of cellular therapies to treat cancer, inherited immune deficiencies, hemoglobinopathies and viral infections is growing rapidly. The increased interest in cellular therapies has led to the development...

    Authors: David F. Stroncek, Robert P. T. Somerville and Steven L. Highfill
    Citation: Journal of Translational Medicine 2022 20:34
  43. A growing number of clinical trials have shown that regulatory T (Treg) cell transfer may have a favorable effect on the maintenance of self-tolerance and immune homeostasis in different conditions such as graft-...

    Authors: Cristiana Lavazza, Silvia Budelli, Elisa Montelatici, Mariele Viganò, Francesca Ulbar, Lucia Catani, Marta Giulia Cannone, Sara Savelli, Elisa Groppelli, Lorenza Lazzari, Roberto M. Lemoli, Matteo Cescon, Gaetano La Manna, Rosaria Giordano and Tiziana Montemurro
    Citation: Journal of Translational Medicine 2022 20:14
  44. Chimeric antigen receptor (CAR) or T-cell receptor (TCR) engineered T-cell therapy has recently emerged as a promising adoptive immunotherapy approach for the treatment of hematologic malignancies and solid tu...

    Authors: Yihua Cai, Michaela Prochazkova, Chunjie Jiang, Hannah W. Song, Jianjian Jin, Larry Moses, Nikolaos Gkitsas, Robert P. Somerville, Steven L. Highfill, Sandhya Panch, David F. Stroncek and Ping Jin
    Citation: Journal of Translational Medicine 2021 19:523
  45. Knee osteoarthritis is the most prevalent joint disease and a frequent cause of pain, functional loss and disability. Conventional treatments have demonstrated only modest clinical benefits whereas cell-based ...

    Authors: José María Lamo-Espinosa, Felipe Prósper, Juan F. Blanco, Fermín Sánchez-Guijo, Mercedes Alberca, Verónica García, Margarita González-Vallinas and Javier García-Sancho
    Citation: Journal of Translational Medicine 2021 19:506
  46. Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved remarkable effect in hematological ...

    Authors: Meng Zhang, Xin Jin, Rui Sun, Xia Xiong, Jiaxi Wang, Danni Xie and MingFeng Zhao
    Citation: Journal of Translational Medicine 2021 19:499
  47. CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by...

    Authors: Khadijeh Alishah, Matthias Birtel, Elham Masoumi, Leila Jafarzadeh, Hamid Reza Mirzaee, Jamshid Hadjati, Ralf-Holger Voss, Mustafa Diken and Sedighe Asad
    Citation: Journal of Translational Medicine 2021 19:482
  48. Gene transfer is an important tool for cellular therapies. Lentiviral vectors are most effectively transferred into lymphocytes or hematopoietic progenitor cells using spinoculation. To enable cGMP (current Go...

    Authors: Victoria Ann Remley, Jianjian Jin, Sarmila Sarkar, Larry Moses, Michaela Prochazkova, Yihua Cai, Lipei Shao, Hui Liu, Tatyana Fuksenko, Ping Jin, David F. Stroncek and Steven L. Highfill
    Citation: Journal of Translational Medicine 2021 19:474
  49. Nucleotide mutations in the ABO gene may reduce the activity of glycosyltransferase, resulting in lower levels of A or B antigen expression in red blood cells. Six known splice sites have been identified accordin...

    Authors: Xiaozhen Hong, Yanling Ying, Jingjing Zhang, Shu Chen, Xianguo Xu, Ji He and Faming Zhu
    Citation: Journal of Translational Medicine 2021 19:470

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.458 - SNIP (Source Normalized Impact per Paper)
    1.544 - SJR (SCImago Journal Rank)

    2023 Speed
    9 days submission to first editorial decision for all manuscripts (Median)
    86 days submission to accept (Median)

    2023 Usage 
    4,999,990 downloads
    8,678 Altmetric mentions